| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Pregnancy cat. | C [1] |
| Legal status | ? |
| Routes | Inhalation |
| Identifiers | |
| ATC code | R03AK04 |
| ChemSpider | 21106326 |
| (what is this?) (verify) |
|
The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma(not an FDA approved usage)[2]. It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations under the trade name Combivent. Besides, it is marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva.
Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries.
DuoNeb has been a subject of recent Medicare and U.S. Food and Drug Administration (FDA) controversy. FDA has moved for regulation of generic competition to commercial product whereas Medicare has moved to limit reimbursement of commercial product. Dispute resolution will have a material economic impact on leading respiratory service providers, as well as patients.
National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051..
|
||||||||||||||||||||||||||||||||||||||||||||||||